Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates

mAbs

Volumn 5, Issue 1, 2013, Pages 13-21

  Ritchie, Michael ^a   Tchistiakova, Lioudmila ^a   Scott, Nathan ^a  

^a PFIZER INC   (United States)

Author keywords

ADC; Affinity; Antibody engineering; Endocytosis; Endosomal sorting; HER2; Linker payload; Lysosome

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; CD31 ANTIGEN; DYNAMIN; GUANOSINE TRIPHOSPHATASE; LOW DENSITY LIPOPROTEIN RECEPTOR; SUBTILISIN; SULFIDE; TOCILIZUMAB; TRANSFERRIN RECEPTOR; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; BINDING AFFINITY; CELL MIGRATION; DRUG CONJUGATION; DRUG EFFICACY; ENDOCYTOSIS; ENDOSOME; HUMAN; MOLECULAR SIZE; NONHUMAN; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ENDOCYTOSIS; ENDOSOMES; HUMANS; IMMUNOCONJUGATES; MICE; NEOPLASMS; PROTEIN ENGINEERING; PROTEIN TRANSPORT; RECEPTOR, ERBB-2;

EID: 84872846418     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.22854     Document Type: Review

References (74)

1. Adams G.P., Weiner LM Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23:1147-57; PMID:16151408; http://dx.doi.org/10.1038/nbt1137
2. Beck A, Haeuw J F, Wurch T, Goetsch L., Bailly C, Corvaïa N. The next generation of antibody-drug conjugates comes of age. Discov Med 2010; 10:329-39; PMID:21034674
3. Mayor S, Pagano RE Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 2007; 8:603-12; PMID:17609668; http://dx.doi.org/10.1038/nrm2216
4. Le Roy C., Wrana JL Clathrin-and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 2005; 6:112-26; PMID:15687999; http://dx.doi.org/10.1038/nrm1571
5. Höning S., Ricotta D, Krauss M., Späte K, Spolaore B., Motley A, et al Phosphatidylinositol-(4, 5)-bisphosphate regulates sorting signal recognition by the clathrin-associated adaptor complex AP2. Mol Cell 2005; 18:519-31; PMID:15916959; http://dx.doi.org/10.1016/j.molcel.2005.04.019
6. Owen DJ, Evans PR A structural explanation for the recognition of tyrosine-based endocytotic signals. Science 1998; 282:1327-32; PMID:9812899; http://dx.doi.org/10.1126/science.282.5392.1327
7. McMahon H.T., Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 2011; 12:517-33; PMID:21779028; http://dx.doi.org/10.1038/nrm3151
8. Wigge P, Köhler K, Vallis Y., Doyle CA, Owen D, Hunt S P, et al Amphiphysin heterodimers: potential role in clathrin-mediated endocytosis. Mol Biol Cell 1997; 8:2003-15; PMID:9348539
9. Ferguson SM, Raimondi A, Paradise S., Shen H, Mesaki K, Ferguson A., et al Coordinated actions of actin and BAR proteins upstream of dynamin at endocytic clathrin-coated pits. Dev Cell 2009; 17:811-22; PMID:20059951; http://dx.doi.org/10.1016/j.devcel.2009.11.005
10. Sundborger A, Soderblom C, Vorontsova O., Evergren E, Hinshaw JE, Shupliakov O. An endophilin-dynamin complex promotes budding of clathrin-coated vesicles during synaptic vesicle recycling. J Cell Sci 2011; 124:133-43; PMID:21172823; http://dx.doi.org/10.1242/jcs.072686
11. Roux A, Uyhazi K, Frost A., De Camilli P. GTP-dependent twisting of dynamin implicates constriction and tension in membrane fission. Nature 2006; 441:528-31; PMID:16648839; http://dx.doi.org/10.1038/nature04718
12. Stowell MH, Marks B, Wigge P., McMahon HT Nucleotide-dependent conformational changes in dynamin: evidence for a mechanochemical molecular spring. Nat Cell Biol 1999; 1:27-32; PMID:10559860; http://dx.doi.org/10.1038/ 8997
13. Sweitzer SM, Hinshaw JE Dynamin undergoes a GTP-dependent conformational change causing vesiculation. Cell 1998; 93:1021-9; PMID:9635431; http://dx.doi.org/10.1016/S0092-8674(00)81207-6
14. Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol 2009; 10:513-25; PMID:19603039; http://dx.doi.org/10.1038/nrm2728
15. Helenius A, Marsh M. Endocytosis of enveloped animal viruses. Ciba Found Symp 1982; 59-76; PMID: 6129957
16. van Weering J.R., Verkade P, Cullen PJ SNX-BAR-mediated endosome tubulation is co-ordinated with endosome maturation. Traffic 2012; 13:94-107; PMID:21973056; http://dx.doi.org/10.1111/j.1600-0854.2011.01297.x
17. Yamashiro DJ, Maxfield FR Acidification of morphologically distinct endosomes in mutant and wild-type Chinese hamster ovary cells. J Cell Biol 1987; 105:2723-33; PMID:2447098; http://dx.doi.org/10.1083/jcb.105.6.2723
18. Maxfield FR, McGraw TE Endocytic recycling. Nat Rev Mol Cell Biol 2004; 5:121-32; PMID:15040445; http://dx.doi.org/10.1038/nrm1315
19. Choudhury A, Sharma DK, Marks D.L., Pagano RE Elevated endosomal cholesterol levels in Niemann-Pick cells inhibit rab4 and perturb membrane recycling. Mol Biol Cell 2004; 15:4500-11; PMID:15292453; http://dx.doi.org/10. 1091/mbc.E04-05-0432
20. Radhakrishna H, Donaldson JG ADP-ribosylation factor 6 regulates a novel plasma membrane recycling pathway. J Cell Biol 1997; 139:49-61; PMID:9314528; http://dx.doi.org/10.1083/jcb.139.1.49
21. Naslavsky N, Weigert R, Donaldson JG Characterization of a nonclathrin endocytic pathway: membrane cargo and lipid requirements. Mol Biol Cell 2004; 15:3542-52; PMID:15146059; http://dx.doi.org/10.1091/mbc.E04-02-0151
22. Naslavsky N, Weigert R, Donaldson JG Convergence of non-clathrin-and clathrin-derived endosomes involves Arf6 inactivation and changes in phosphoinositides. Mol Biol Cell 2003; 14:417-31; PMID:12589044; http://dx.doi.org/10.1091/mbc.02-04-0053
23. Huotari J, Helenius A. Endosome maturation. EMBO J 2011; 30:3481-500; PMID:21878991; http://dx.doi.org/10.1038/emboj.2011.286
24. Roederer M, Bowser R, Murphy R F. Kinetics and temperature dependence of exposure of endocytosed material to proteolytic enzymes and low pH: evidence for a maturation model for the formation of lysosomes. J Cell Physiol 1987; 131:200-9; PMID:2438291; http://dx.doi.org/10.1002/jcp.1041310209
25. Russell MR, Nickerson D P, Odorizzi G. Molecular mechanisms of late endosome morphology, identity and sorting. Curr Opin Cell Biol 2006; 18:422-8; PMID:16781134; http://dx.doi.org/10.1016/j.ceb.2006.06.002
26. Karin M, Mintz B. Receptor-mediated endocytosis of transferrin in developmentally totipotent mouse terato-carcinoma stem cells. J Biol Chem 1981; 256:3245-52; PMID:6259157
27. Dautry-Varsat A., Ciechanover A, Lodish H F. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci U S A 1983; 80:2258-62; PMID:6300903; http://dx.doi.org/10.1073/pnas.80.8.2258
28. Trivedi RR, Bhattacharyya S. Constitutive internalization and recycling of metabotropic glutamate receptor 5 (mGluR5). Biochem Biophys Res Commun 2012; 427:185-90; PMID:22995293; http://dx.doi.org/10.1016/j.bbrc.2012.09.040
29. Pellinen T, Ivaska J. Integrin traffic. J Cell Sci 2006; 119:3723-31; PMID:16959902; http://dx.doi.org/10.1242/jcs.03216
30. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000; 19:6102-14; PMID:11156523; http://dx.doi.org/10. 1038/sj.onc.1203973
31. Harford J, Wolkoff AW, Ashwell G, Klausner RD Monensin inhibits intracellular dissociation of asialoglycoproteins from their receptor. J Cell Biol 1983; 96:1824-8; PMID:6304116; http://dx.doi.org/10.1083/jcb.96.6.1824
32. Harford J, Bridges K, Ashwell G., Klausner RD Intracellular dissociation of receptor-bound asialogly-coproteins in cultured hepatocytes. A pH-mediated nonlysosomal event. J Biol Chem 1983; 258:3191-7; PMID:6298227
33. Roepstorff K, Grandal MV, Henriksen L, Knudsen S.L., Lerdrup M., Grøvdal L, et al Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 2009; 10:1115-27; PMID:19531065; http://dx.doi.org/10.1111/j.1600-0854.2009.00943.x
34. Ellinger I, Schwab M, Stefanescu A., Hunziker W, Fuchs R. IgG transport across trophoblast-derived BeWo cells: a model system to study IgG transport in the placenta. Eur J Immunol 1999; 29:733-44; PMID:10092075; http://dx.doi.org/ 10.1002/(SICI) 1521-4141(199903) 29:03<733::AID-IMMU733>3.0.CO;2-C
35. Rocca A, Lamaze C, Subtil A., Dautry-Varsat A. Involvement of the ubiquitin/proteasome system in sorting of the interleukin 2 receptor beta chain to late endocytic compartments. Mol Biol Cell 2001; 12:1293-301; PMID:11359922
36. Jones SM, Foreman SK, Shank B.B., Kurten RC EGF receptor downregulation depends on a trafficking motif in the distal tyrosine kinase domain. Am J Physiol Cell Physiol 2002; 282:C420-33; PMID:11832327
37. Shenoy SK, McDonald PH, Kohout T.A., Lefkowitz RJ Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 2001; 294:1307-13; PMID:11588219; http://dx.doi.org/10. 1126/science.1063866
38. Fujita Y, Krause G, Scheffner M., Zechner D, Leddy HE, Behrens J, et al Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol 2002; 4:222-31; PMID:11836526; http://dx.doi.org/10.1038/ncb758
39. Ober RJ, Martinez C, Lai X., Zhou J, Ward ES Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci U S A 2004; 101:11076-81; PMID:15258288; http://dx.doi.org/10. 1073/pnas.0402970101
40. Mircic M, Kavanaugh A. The clinical efficacy of tocilizumab in rheumatoid arthritis. Drugs Today (Barc) 2009; 45:189-97; PMID:19436841; http://dx.doi.org/10.1358/dot.2009.45.3.1343794
41. Igawa T, Ishii S, Tachibana T., Maeda A, Higuchi Y, Shimaoka S., et al Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010; 28:1203-7; PMID:20953198; http://dx.doi.org/10.1038/nbt.1691
42. Chaparro-Riggers J., Liang H, DeVay R.M., Bai L., Sutton JE, Chen W, et al Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem 2012; 287:11090-7; PMID:22294692; http://dx.doi.org/10.1074/jbc.M111.319764
43. Tettamanzi MC, Keeler C, Meshack S., Hodsdon ME Analysis of site-specific histidine protonation in human prolactin. Biochemistry 2008; 47:8638-47; PMID:18652486; http://dx.doi.org/10.1021/bi800444t
44. Keeler C, Jablonski EM, Albert Y.B., Taylor BD, Myszka DG, Clevenger CV, et al The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range. Biochemistry 2007; 46:2398-410; PMID:17279774; http://dx.doi.org/10.1021/bi061958v
45. Kulkarni MV, Tettamanzi MC, Murphy J.W., Keeler C., Myszka DG, Chayen NE, et al Two independent histidines, one in human prolactin and one in its receptor, are critical for pH-dependent receptor recognition and activation. J Biol Chem 2010; 285:38524-33; PMID:20889499; http://dx.doi.org/10.1074/jbc.M110. 172072
46. Rudnick SI, Lou J, Shaller C.C., Tang Y., Klein-Szanto AJ, Weiner LM, et al Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 2011; 71:2250-9; PMID:21406401; http://dx.doi.org/10.1158/0008-5472.CAN-10-2277
47. Fujimori K, Covell DG, Fletcher J.E., Weinstein JN Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab') 2, and Fab in tumors. Cancer Res 1989; 49:5656-63; PMID:2790783
48. Weinstein JN, Eger RR, Covell D.G., Black CD, Mulshine J, Carrasquillo JA, et al The pharmacology of monoclonal antibodies. Ann N Y Acad Sci 1987; 507:199-210; PMID:3327413; http://dx.doi.org/10.1111/j.1749-6632.1987.tb45802.x
49. Juweid M, Neumann R, Paik C., Perez-Bacete MJ, Sato J, van Osdol W, et al Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992; 52:5144-53; PMID:1327501
50. Eger RR, Covell DG, Carrasquillo J.A., Abrams PG, Foon KA, Reynolds JC, et al Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans. Cancer Res 1987; 47:3328-36; PMID:3581071
51. Ingle GS, Chan P, Elliott J.M., Chang WS, Koeppen H, Stephan J P, et al High CD21 expression inhibits inter-nalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br J Haematol 2008; 140:46-58; PMID:17991300
52. Ackerman ME, Pawlowski D, Wittrup KD Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol Cancer Ther 2008; 7:2233-40; PMID:18645032; http://dx.doi.org/10.1158/1535-7163.MCT-08-0067
53. Thurber GM, Schmidt MM, Wittrup KD Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008; 60:1421-34; PMID:18541331; http://dx.doi.org/10.1016/j.addr.2008.04.012
54. Reddy S, Shaller CC, Doss M, Shchaveleva I., Marks JD, Yu JQ, et al Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res 2011; 17:1509-20; PMID:21177408; http://dx.doi.org/10.1158/1078-0432.CCR-10-1654
55. Schier R, Bye J, Apell G., McCall A, Adams G P, Malmqvist M, et al Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol 1996; 255:28-43; PMID:8568873; http://dx.doi.org/10.1006/jmbi.1996.0004
56. Schier R, McCall A, Adams G P, Marshall KW, Merritt H, Yim M., et al Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 1996; 263:551-67; PMID:8918938; http://dx.doi.org/10.1006/jmbi.1996.0598
57. Adams G.P., Schier R, McCall A.M., Simmons HH, Horak EM, Alpaugh RK, et al High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61:4750-5; PMID:11406547
58. Zahnd C, Kawe M, Stumpp M.T., de Pasquale C, Tamaskovic R, Nagy-Davidescu G, et al Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010; 70:1595-605; PMID:20124480; http://dx.doi.org/10.1158/0008-5472.CAN-09-2724
59. Schmidt MM, Wittrup KD A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009; 8:2861-71; PMID:19825804; http://dx.doi.org/10.1158/1535-7163.MCT-09-0195
60. Polson AG, Calemine-Fenaux J, Chan P., Chang W, Christensen E, Clark S., et al Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009; 69:2358-64; PMID:19258515; http://dx.doi. org/10.1158/0008-5472.CAN-08-2250
61. Doronina SO, Toki BE, Torgov M.Y., Mendelsohn BA, Cerveny CG, Chace D F, et al Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21:778-84; PMID:12778055; http://dx.doi.org/10. 1038/nbt832
62. Kovtun YV, Audette CA, Ye Y, Xie H., Ruberti MF, Phinney SJ, et al Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006; 66:3214-21; PMID:16540673; http://dx.doi.org/10.1158/0008-5472.CAN-05-3973
63. Erickson HK, Park PU, Widdison W.C., Kovtun YV, Garrett LM, Hoffman K, et al Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intra-cellular processing. Cancer Res 2006; 66:4426-33; PMID:16618769; http://dx.doi.org/10.1158/0008-5472.CAN-05- 4489
64. Tanaka M, Kano Y, Akutsu M., Tsunoda S, Izumi T, Yazawa Y., et al The cytotoxic effects of gemtu-zumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Anticancer Res 2009; 29:4589-96; PMID:20032408
65. Lewis Phillips G.D., Li G, Dugger D.L., Crocker LM, Parsons KL, Mai E, et al Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68:9280-90; PMID:19010901; http://dx.doi.org/10.1158/0008-5472.CAN-08-1776
66. Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson H.A., et al The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastu-zumab maytansinoid conjugates. Mol Cancer Ther 2012; 11:1133-42; PMID:22408268; http://dx.doi.org/10.1158/1535- 7163.MCT-11-0727
67. Sievers EL, Senter PD Antibody-Drug Conjugates in Cancer Therapy[Epub ahead of print]. Annu Rev Med 2012; PMID:23043493; http://dx.doi.org/10.1146/ annurev-med-050311-201823
68. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 2005; 5:543-9; PMID:16087399; http://dx.doi.org/10. 1016/j.coph.2005.04.017
69. Haeuw J.F., Caussanel V, Beck A. Immunoconjugates, drug-armed antibodies to fight against cancer. Med Sci (Paris) 2009; 25:1046-52; PMID:20035677; http://dx.doi.org/10.1051/medsci/200925121046
70. LoRusso PM, Weiss D, Guardino E., Girish S, Sliwkowski MX Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 2011; 17:6437-47; PMID:22003071; http://dx.doi.org/10.1158/1078-0432.CCR-11-0762
71. Verma S, Miles D, Gianni L., Krop IE, Welslau M, Baselga J, et al; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. [Epub ahead of print]. N Engl J Med 2012; 367:1783-91; PMID:23020162; http://dx.doi.org/10.1056/NEJMoa1209124
72. Bross P.F., Beitz J, Chen G., Chen XH, Duffy E, Kieffer L, et al Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7:1490-6; PMID:11410481
73. Hamann PR, Hinman LM, Beyer C.F., Lindh D., Upeslacis J, Flowers DA, et al An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 2002; 13:40-6; PMID:11792177; http://dx.doi.org/10.1021/bc0100206
74. Löwenberg B., Beck J, Graux C., van Putten W, Schouten HC, Verdonck L F, et al; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German Austrian AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK). Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood 2010; 115:2586-91; PMID:20103782; http://dx.doi.org/10.1182/blood-2009-10-246470